STOCK TITAN
  1. Home
  2. Sec-filings
  3. VMD
  4. [Form 4] VIEMED HEALTHCARE, INC. Insider Trading Activity

Viemed Healthcare (VMD) GC granted RSUs and phantom share units

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Viemed Healthcare General Counsel Jeremy Trahan reported multiple equity compensation transactions. On January 17, 2026, 4,884 restricted stock units and 1,221 cash-settled phantom share units vested, resulting in the acquisition of the same number of common shares. To cover tax obligations tied to the RSU vesting, 1,595 common shares were withheld at a per share value of $7.33, leaving 28,792 common shares held directly after the transactions.

On January 19, 2026, Trahan was granted 50,360 new restricted stock units and 12,590 phantom share units. Both awards vest in three equal annual installments beginning on the first anniversary of their grant date. Each RSU represents a right to receive one common share, while each phantom share represents the cash value of one common share on the vesting date.

Positive

  • None.

Negative

  • None.
Insider Trahan Jeremy
Role General Counsel
Type Security Shares Price Value
Grant/Award Restricted Stock Units 50,360 $0.00 --
Grant/Award Phantom Share Units 12,590 $0.00 --
Exercise Restricted Stock Units 4,884 $0.00 --
Exercise Phantom Share Units 1,221 $0.00 --
Exercise Common Shares 4,884 $0.00 --
Tax Withholding Common Shares 1,595 $7.33 $12K
Exercise Common Shares 1,221 $0.00 --
Disposition Common Shares 1,221 $7.33 $9K
Holdings After Transaction: Restricted Stock Units — 50,360 shares (Direct); Phantom Share Units — 12,590 shares (Direct); Common Shares — 30,387 shares (Direct)
Footnotes (1)
  1. Each Restricted Stock Unit (RSU) represents a contingent right to receive one common share. Shares that were withheld by the issuer to satisfy the reporting person's tax obligation resulting from the vesting of restricted stock units. Per share value is based on the market closing price of the common shares for January 16, 2026. Represents vesting of cash-settled phantom shares granted under the Issuer's Phantom Share Unit Plan. Each phantom share is the economic equivalent of one Company common share. The settlement of the phantom shares for cash is reported on this Form 4 as a disposition of the phantom shares being settled in exchange for the acquisition of the underlying Company common shares, and a simultaneous disposition of the underlying Company common shares to the Company for cash. Restricted Stock Units (RSUs) granted to reporting person on January 17, 2023, which vest in three equal annual installments beginning on the first anniversary of the grant date. Represents an award granted on January 17, 2023 under the Issuer's Phantom Share Unit Plan which vests in three equal annual installments beginning on the first anniversary of the grant date. Restricted Stock Units (RSUs) granted to reporting person on January 19, 2026, which vest in three equal annual installments beginning on the first anniversary of the grant date. Each phantom share represents a right to receive the cash value of one share of the Issuer's common shares which will be determined based on the Issuer's share price on the vesting date. Represents an award granted on January 19, 2026 under the Issuer's Phantom Share Unit Plan which vests in three equal annual installments beginning on the first anniversary of the grant date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Trahan Jeremy
(Last) (First) (Middle)
625 E. KALISTE SALOOM RD.
(Street)
LAFAYETTE LA 70508
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
VIEMED HEALTHCARE, INC. [ VMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
General Counsel
3. Date of Earliest Transaction (Month/Day/Year)
01/17/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 01/17/2026 M 4,884 A (1) 30,387 D
Common Shares 01/17/2026 F 1,595(2) D $7.33(3) 28,792 D
Common Shares 01/17/2026 M 1,221 A (4) 30,013 D
Common Shares 01/17/2026 D 1,221 D $7.33(3) 28,792 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 01/17/2026 M 4,884 (5) 01/17/2026 Common Shares 4,884 $0 0 D
Phantom Share Units (4) 01/17/2026 M 1,221 (6) 01/17/2026 Common Shares 1,221 (4) 0 D
Restricted Stock Units (1) 01/19/2026 A 50,360 (7) 01/19/2029 Common Shares 50,360 $0 50,360 D
Phantom Share Units (8) 01/19/2026 A 12,590 (9) 01/19/2029 Common Shares 12,590 $0 12,590 D
Explanation of Responses:
1. Each Restricted Stock Unit (RSU) represents a contingent right to receive one common share.
2. Shares that were withheld by the issuer to satisfy the reporting person's tax obligation resulting from the vesting of restricted stock units.
3. Per share value is based on the market closing price of the common shares for January 16, 2026.
4. Represents vesting of cash-settled phantom shares granted under the Issuer's Phantom Share Unit Plan. Each phantom share is the economic equivalent of one Company common share. The settlement of the phantom shares for cash is reported on this Form 4 as a disposition of the phantom shares being settled in exchange for the acquisition of the underlying Company common shares, and a simultaneous disposition of the underlying Company common shares to the Company for cash.
5. Restricted Stock Units (RSUs) granted to reporting person on January 17, 2023, which vest in three equal annual installments beginning on the first anniversary of the grant date.
6. Represents an award granted on January 17, 2023 under the Issuer's Phantom Share Unit Plan which vests in three equal annual installments beginning on the first anniversary of the grant date.
7. Restricted Stock Units (RSUs) granted to reporting person on January 19, 2026, which vest in three equal annual installments beginning on the first anniversary of the grant date.
8. Each phantom share represents a right to receive the cash value of one share of the Issuer's common shares which will be determined based on the Issuer's share price on the vesting date.
9. Represents an award granted on January 19, 2026 under the Issuer's Phantom Share Unit Plan which vests in three equal annual installments beginning on the first anniversary of the grant date.
Remarks:
/s/ Jesse Bergeron, Attorney-in-Fact 01/21/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did Viemed Healthcare (VMD) report for its General Counsel?

The General Counsel, Jeremy Trahan, reported vesting of existing restricted stock units and phantom share units on January 17, 2026, along with new grants of restricted stock units and phantom share units on January 19, 2026.

How many Viemed Healthcare (VMD) RSUs vested and were settled on January 17, 2026?

On January 17, 2026, 4,884 restricted stock units vested, resulting in the acquisition of 4,884 common shares by the General Counsel.

How many Viemed Healthcare (VMD) phantom share units vested on January 17, 2026?

On January 17, 2026, 1,221 phantom share units vested. These cash-settled phantom shares were exchanged for 1,221 common shares and simultaneously settled back to the company for cash.

How many Viemed Healthcare (VMD) common shares did the General Counsel own after the January 17, 2026 transactions?

After the reported transactions on January 17, 2026, the General Counsel directly held 28,792 common shares of Viemed Healthcare.

What new Viemed Healthcare (VMD) restricted stock units were granted on January 19, 2026?

On January 19, 2026, the General Counsel received a grant of 50,360 restricted stock units, which vest in three equal annual installments starting on the first anniversary of the grant date.

What are the details of the new Viemed Healthcare (VMD) phantom share unit grant?

On January 19, 2026, the General Counsel was granted 12,590 phantom share units under the Phantom Share Unit Plan, vesting in three equal annual installments beginning on the first anniversary of the grant date. Each phantom share represents the cash value of one common share on the vesting date.

Why were some Viemed Healthcare (VMD) shares withheld at $7.33 per share?

A total of 1,595 common shares were withheld by Viemed Healthcare at $7.33 per share to satisfy the General Counsel’s tax obligations arising from the vesting of restricted stock units, based on the market closing price on January 16, 2026.